Ventyx Biosciences Inc (VTYX)
4.80
-0.01
(-0.21%)
USD |
NASDAQ |
May 31, 16:00
4.79
-0.01
(-0.21%)
After-Hours: 20:00
Ventyx Biosciences Shareholders Equity (Quarterly): 307.00M for March 31, 2024
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 307.00M |
December 31, 2023 | 243.92M |
September 30, 2023 | 283.64M |
June 30, 2023 | 327.81M |
March 31, 2023 | 371.62M |
December 31, 2022 | 353.90M |
September 30, 2022 | 383.53M |
Date | Value |
---|---|
June 30, 2022 | 243.15M |
March 31, 2022 | 259.12M |
December 31, 2021 | 279.20M |
September 30, 2021 | -87.62M |
June 30, 2021 | -75.86M |
December 31, 2020 | -30.65M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
-87.62M
Minimum
Sep 2021
383.53M
Maximum
Sep 2022
219.90M
Average
279.20M
Median
Dec 2021
Shareholders Equity (Quarterly) Benchmarks
Anavex Life Sciences Corp | 134.96M |
Checkpoint Therapeutics Inc | -10.25M |
CERo Therapeutics Holdings Inc | -- |
Lexicon Pharmaceuticals Inc | 288.87M |
Altimmune Inc | 172.94M |
Shareholders Equity (Quarterly) Related Metrics
Total Assets (Quarterly) | 332.08M |
Total Liabilities (Quarterly) | 25.08M |